Abiomed (ABMD) Alert: Johnson Fistel Launches Investigation into Abiomed, Inc.; Investors Encouraged to Contact Firm

SAN DIEGO, Dec. 12, 2019

Specifically, the investigation seeks to determine whether certain statements regarding the Company's Impella heart pumps were false and misleading when made.  On November 17, 2019, clinical studies were presented at the American Heart Association's ("AHA") annual meeting in Philadelphia that presented data questioning the safety and effectiveness of Abiomed's Impella heart pumps.  Following this news, the price of Abiomed shares plummeted $45.14 per share to close at $178.09 per share on Monday, November 18, 2019, a decline of more than 20%.

If you lost money, realized or unrealized on your Abiomed investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471.  If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[click here to join this action]